Background and objective: Pneumothorax is a comorbidity in patients with idiopathic pulmonary fibrosis (IPF). However, its incidence, risk factors and prognostic significance in IPF remain unclear. The aim of this study was to clarify the incidence and prognostic significance of pneumothorax in patients with IPF, and to further investigate the risk factors for its onset. Methods: Eighty-four consecutive patients with IPF based on the consensus guideline were included in this study. We retrospectively reviewed the medical records, pulmonary function tests and chest high-resolution computed tomography images, and determined the incidence of pneumothorax. The prognostic significance of pneumothorax was evaluated using the Cox proportional hazards model analysis with time-dependent covariates. We also assessed the cumulative incidence and the risk factors for pneumothorax. Results: Of the 84 patients, 17 (20.2%) developed pneumothorax. The cumulative incidence of pneumothorax was 8.5%, 12.5% and 17.7% at 1, 2 and 3 years, respectively. Univariate analysis demonstrated that pneumothorax was significantly related to poor prognosis (hazards ratio, 2.99; P = 0.002). Multivariate analysis, adjusting for sex, age and forced vital capacity (% predicted), revealed that pneumothorax was an independent predictor of poor outcome in IPF (hazards ratio, 2.85; P = 0.006). Lower BMI and the presence of extensive reticular abnormalities were significantly associated with developing pneumothorax. Conclusion: These results confirm that patients with IPF often develop pneumothorax during their clinical course and that the onset of pneumothorax predicts a poor outcome.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, that is limited to the lungs. 1 IPF causes progressive decline in subjective and objective pulmonary function, with a median survival of 2 to 5 years from the time of diagnosis. [1] [2] [3] [4] [5] Although the major cause of death in IPF is respiratory failure, several complicating illnesses such as heart failure, infections and lung cancer also contribute to clinical deterioration and poor prognosis. 6 In clinical practice, intractable pneumothorax may be encountered in patients with IPF; however, few studies have examined the prognostic significance of pneumothorax in IPF. A few studies have noted the occurrence of pneumothorax in patients with IPF, [7] [8] [9] whereas its cumulative incidence was unclear in those 
SUMMARY AT A GLANCE
We evaluated prognostic significance of pneumothorax and the risk factors for its onset in patients with idiopathic pulmonary fibrosis (IPF). We demonstrate that the onset of pneumothorax predicts a poor outcome in the patients with IPF. Lower BMI and the presence of extensive reticular abnormalities are associated with developing pneumothorax. studies. Most of the prior studies examining the occurrence of pneumothorax in IPF pre-date the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (LATA) diagnostic guidelines for IPF, published in 2011. Thus, the incidence and prognostic significance of pneumothorax in IPF as diagnosed using the 2011 guidelines are not fully understood.
Identifying the risk factors for pneumothorax in patients with IPF is also important. Being male, and having a tall and thin stature, a history of smoking and subpleural bullae are known risk factors for primary spontaneous pneumothorax. 10, 11 However, few studies have focused on determining the risk factors for pneumothorax in IPF patients specifically.
We undertook this current study to clarify the incidence and prognostic significance of pneumothorax in patients with IPF, and to further investigate the risk factors for its onset.
METHODS

Study subjects
We retrospectively reviewed the clinical records of 358 consecutive patients with interstitial lung diseases (ILDs) evaluated at Hamamatsu University Hospital (Hamamatsu, Japan) between January 2000 and December 2014. Among them, 102 patients were diagnosed as having IPF based on the diagnostic criteria of the ATS/ERS/JRS/LATA diagnostic guidelines.
1 Eight patients were excluded from this study since their observation periods were less than 3 months. Ten patients who had concurrent advanced cancer at the time of IPF diagnosis were also excluded. Thus, 84 patients with IPF were included in this study. Among them, 57 patients (67.9%) were diagnosed with IPF by the presence of the usual interstitial pneumonia (UIP) pattern on HRCT images, and 27 patients (32.1%) who had a possible UIP pattern on HRCT were diagnosed with IPF via surgical lung biopsies. This study was approved by the Institutional Review Board of the Hamamatsu University School of Medicine (approval number: .
Clinical data collection
We reviewed the included patients' medical records, laboratory data, pulmonary function data and lung HRCT image findings obtained at the time of IPF diagnosis. We also reviewed the use of prednisolone, immunosuppressive agents (e.g. cyclophosphamide, cyclosporin and tacrolimus) and antifibrotic agents (including pirfenidone and nintedanib) during the observation period. Diagnoses of acute exacerbation of IPF were made based on the following observations: worsening of dyspnoea within 30 days or less, new bilateral radiographical opacities and the absence of infection or any other identifiable aetiology. 12 
Radiological analysis
The HRCT images acquired at initial diagnosis of IPF were reviewed by two expert thoracic radiologists who had no access to the patients' clinical data. These images were comprised of 1.0-1.5-mm collimated sections taken at 10-mm intervals. The HRCT findings, including the presence of a reticular pattern, honeycombing, centrilobular emphysema, paraseptal emphysema and traction bronchiectasis were interpreted according to the Fleischner Society criteria, 13 with slight modifications. The HRCT criteria for the UIP pattern were defined as subpleural and basal-predominant reticulation with radiological honeycombing, with or without traction bronchiectasis and without atypical findings for IPF. 1 Pleuroparenchymal thickening was defined as a dense subpleural consolidation.
14 The extent of reticular abnormalities (i.e. reticular pattern and honeycombing) and emphysema were semiquantitatively scored: Grade 0 (0%), Grade 1 (<25%), Grade 2 (25-50%), Grade 3 (50-75%) and Grade 4 (>75%). All patients underwent chest radiography or HRCT every 3-6 months during their observation period. Three pulmonologists reviewed the medical records and all radiological images (chest radiographs or HRCT images) to confirm the onset of pneumothorax.
Statistical analysis
Data are presented as the number (%) or median (interquartile ranges). Fisher's exact test or the MannWhitney U test were used for the between-group comparisons. The cumulative incidence of pneumothorax was evaluated using Gray's test, considering any cause of death an important competing factor. The observation period for survival was calculated from the date of initial IPF diagnosis to the last date of contact or time of death. To identify the predictive factors of poor outcome, we used univariate and multivariate Cox proportional hazards model analyses with time-dependent covariates. Furthermore, we assessed the predictive factors of the onset of pneumothorax using the Cox proportional hazards model analysis. The survival curves were generated using the Kaplan-Meier method. The log-rank test was employed to compare the survival rate between the groups of patients. A Pvalue of <0.05 was considered statistically significant for all analyses. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama Japan), which is a graphical user interface for R software (version 2.13.0, The R Foundation for Statistical Computing, Vienna, Austria). 15 
RESULTS
Clinical characteristics
Of the 84 patients diagnosed with IPF, 17 patients (20.2%) developed pneumothorax during their clinical courses, and 67 patients did not. The patients' characteristics are reported in Table 1 . The patients who developed pneumothorax had a lower BMI and lower PaO 2 (partial pressure of oxygen in arterial blood) than those who did not develop pneumothorax (P = 0.037 and 0.019, respectively). There was no significant difference in the results of the pulmonary function tests between the two groups, although the extent of reticular abnormality on HRCT tended to be greater in patients with pneumothorax.
Incidence of pneumothorax in IPF
The cumulative incidence of pneumothorax from the time of IPF diagnosis was 8.5%, 12.5% and 17.7% at 1, 2 and 3 years, respectively ( Fig. 1 ). In patients with pneumothorax, the median time from the diagnosis of IPF to the onset of the first episode of pneumothorax was 13.1 months (quartile range, 7.5-36.1 months).
Treatments and outcomes
The treatments and outcomes of the study subjects are presented in Table 2 . Since some patients were followed-up prior to two new antifibrotic medications (pirfenidone and nintedanib) being developed, 16 ,17 they were treated with prednisolone and immunosuppressive agents. The treatment regimens and the incidence of acute exacerbation were not different between the patients with pneumothorax and those without pneumothorax. A total of 42 patients (14 with pneumothorax, and 28 without) died during the observation period, and the mortality rate was higher in patients with pneumothorax compared to those without (82.4% vs 41.8%, respectively; P = 0.005).
Prognostic significance of pneumothorax in IPF
The results of the univariate analyses demonstrated that higher age, lower BMI, lower forced vital capacity (FVC; % predicted), greater extent of reticular Pneumothorax in patients with IPF abnormalities (≥ Grade 2) and onset of acute exacerbation were significantly associated with worse survival (Table 3) . Pneumothorax was also significantly correlated with poor prognosis (hazards ratio (HR) = 2.99; 95% CI: 1.49-6.03; P = 0.002). The results of the multivariate analysis, adjusting for sex, age and % predicted FVC, revealed that pneumothorax was independently associated with poor prognosis (HR = 2.85; 95% CI: 1.35-6.01; P = 0.006; Table 4 ). Even when adjusting for the other prognostic factors, pneumothorax was an independent predictor of overall mortality (Table S1 , Supplementary Information). The survival curves for the patients with IPF are shown in Figure S1 in Supplementary Information. The median survival in the patients with pneumothorax was 40.3 months, and that without pneumothorax was 53.0 months. The survival rate was significantly lower in patients with pneumothorax than those without pneumothorax. In patients with pneumothorax, the median survival time from the first onset of pneumothorax was 13.3 months (Fig. S2, Supplementary Information) . The causes of death in 14 patients with pneumothorax who died during the observation period were as follows: acute exacerbation of IPF in 4 patients, chronic respiratory failure due to deterioration of IPF in 4 patients, infection in 4 patients and sudden death from unknown causes in 2 patients. Among the 17 patients with pneumothorax, 12 patients (70.6%) experienced recurrences of pneumothorax, and a total of 36 episodes of pneumothorax were observed. We compared features between the single episode group (n = 5) and the recurrence group (n = 12) in Table S2 in Supplementary Information. There was no significant difference in clinical characteristics, pulmonary function tests and HRCT image findings between the two groups. Seven patients (41.2%) had intractable pneumothorax that necessitated chest drainage up to their time of death.
Risk factors for the onset of pneumothorax in IPF
The factors contributing to the onset of pneumothorax in patients with IPF were analysed using the Cox proportional hazards model analysis (Table 5) Table S3 in Supplementary Information).
DISCUSSION
In the present study, we retrospectively reviewed a cohort of 84 consecutive patients with well-defined IPF and evaluated the incidence and clinical implications of pneumothorax in this group. Seventeen patients (20.2%) developed pneumothorax during the observation period and the cumulative incidence of pneumothorax from the time of IPF diagnosis was 8.5%, 12.5% and 17.7% at 1, 2 and 3 years, respectively. Pneumothorax was significantly associated with worse prognosis. The multivariate analysis revealed that pneumothorax, higher age and lower FVC were all independent predictors of poor outcome in patients with IPF. Furthermore, our findings demonstrated that lower BMI and extensive reticular abnormalities were risk factors for the onset of pneumothorax. These findings reveal that pneumothorax is a common complication in the clinical course of IPF, and clinicians should be aware that the onset of pneumothorax is a serious complication associated with worse survival in IPF.
We have shown that pneumothorax is a significant predictor of poor prognosis in patients with IPF. To date, few studies regarding the clinical significance of secondary spontaneous pneumothorax in IPF are available. Aihara et al. retrospectively reviewed 59 occurrences of pneumothorax in 34 patients with ILD and reported that the median survival time after the first episode of pneumothorax was 18.8 months, suggesting that the prognosis of patients with ILD after developing pneumothorax was poor. 18 However, their study included not only patients with IPF, but also those with other ILDs (e.g. non-specific interstitial pneumonia, ILD associated with collagen tissue disease and sarcoidosis). Since the clinical course, response to treatment and prognosis vary among the subtypes of ILD, the prognostic significance of pneumothorax should be investigated separately. In addition, the development of pneumothorax is a time-dependent factor; therefore, statistical analyses with time-dependent covariates are required to evaluate its prognostic relevance. Our results confirm that pneumothorax is significantly associated with poor outcome in patients diagnosed with IPF based on the current diagnostic criteria. Our results determining the cumulative incidence of pneumothorax indicated that patients with IPF have a continuous risk of developing pneumothorax during their clinical course. One study reported that occurrence of pneumothorax in patients with IPF was 6.4%, 8 and the other reported that was 30.4%. 9 Spontaneous pneumothorax can develop anytime during the clinical course in patients with IPF ( Fig. 1) , which could explain the variance in the incidence of pneumothorax reported in former studies. 8, 9 Identification of the predictive factors for the onset of pneumothorax is of particular importance since our findings confirm that pneumothorax is a serious prognostic factor for IPF. We have shown that lower BMI and greater extent of reticular abnormalities on HRCT were significantly associated with the onset of pneumothorax in patients with IPF. There have been few published investigations concerning the risk factors for the onset of pneumothorax in patients with IPF. Generally, lower BMI is considered a risk factor of primary spontaneous pneumothorax. 10, 11, 19, 20 Similarly, we confirmed that lower BMI was a significant predictor of pneumothorax in patients with IPF. Regarding the relationship between pneumothorax and HRCT findings, Iwasawa et al. examined the computed tomography (CT) findings in patients with IPF with or without pneumothorax, 9 and reported that the increase of fibrotic lesions on HRCT images was greater in IPF patients with pneumothorax than in those without pneumothorax; this suggests that the progression of pulmonary fibrotic changes is associated with the onset of pneumothorax. Consistent with their findings, our data revealed that a greater extent of reticular abnormalities found on HRCT images is one of the risk factors for the onset of pneumothorax in IPF.
Pneumothorax in patients with IPF is often multiepisodic and refractory to treatment. 7, 18, 21 In the present study, 12 (70.6%) of 17 patients who developed pneumothorax experienced recurrences, and 7 patients (41.2%) had intractable pneumothorax that necessitated chest drainage up to the time of death. It is likely that the fibrosis-related rigidity of the lung parenchyma in IPF causes impaired re-expansion of the lungs. 7 Suction drainage is often ineffective due to the requirement of high negative pressure for lung re-expansion in patients with pneumothorax and IPF. 6, 7 Blood-patch and chemical pleurodesis are usually performed as first-line treatments, however, pneumothorax often recurs. 18 When a persistent air leak exists, surgery is considered to be the preferred treatment option. 22 However, patients with secondary spontaneous pneumothorax are usually older, and have greater co-morbidities 23, 24 and higher post-operative mortality due to post-operative complications, 21 such as exacerbation of IPF and infections. Given these intractable conditions of pneumothorax in IPF, it is clear why the onset of pneumothorax is strongly associated with poor prognosis in patients with IPF.
There are some limitations to this study. First, it was retrospective. The observation period and time intervals between examinations were different for each patient, which may have affected the incidence of pneumothorax in the patients with IPF. Second, this study was performed in a single institution and the sample size was small. Finally, the survival rate of the patients with IPF in this study was relatively good compared to that of former studies. [2] [3] [4] [5] Of the 84 study subjects with IPF, 23.8% were found to have interstitial abnormalities on routine chest radiographs in the absence of respiratory symptoms, suggesting the presence of early-stage IPF, which may have led to a relatively better survival rate in this study. To verify our findings of the prognostic significance of pneumothorax and the predictive factors for onset of pneumothorax in IPF, prospective observational studies with larger cohorts are required.
In conclusion, our findings revealed that pneumothorax is a serious co-morbidity of IPF with relatively high incidence, and that pneumothorax predicts poor outcome in patients with IPF. Furthermore, we demonstrated the risk factors for the onset of pneumothorax in the clinical and radiological findings of patients with IPF. This study indicates that clinicians should be aware that pneumothorax is an important prognostic factor in the clinical course of IPF. Figure S1 Kaplan-Meier survival curve in the patients with pneumothorax and those without pneumothorax. Figure S2 Kaplan-Meier survival curve from the onset of pneumothorax in patients with pneumothorax. Table S1 Multivariate models for predictors of mortality in patients with idiopathic pulmonary fibrosis. 
